down arrow

Devonian Health Group, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA2518341078
CAD
0.22
0.07 (46.67%)

Dec 04

TSX

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

0.090.25
Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -2.22%, its profits have risen by 108.8% ; the PEG ratio of the company is 0.3
2

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 27 Million (Micro Cap)

stock-summary
P/E

37.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.10

stock-summary
Return on Equity

3.19%

stock-summary
Price to Book

3.02

Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Apr 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.33%
0%
-8.33%
6 Months
10.0%
0%
10.0%
1 Year
57.14%
0%
57.14%
2 Years
4.76%
0%
4.76%
3 Years
-63.33%
0%
-63.33%
4 Years
-55.1%
0%
-55.1%
5 Years
83.33%
0%
83.33%

Devonian Health Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
67.72%
EBIT Growth (5y)
16.37%
EBIT to Interest (avg)
-2.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0.97
Tax Ratio
10.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.64%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
4.20
EV to EBIT
27.34
EV to EBITDA
18.56
EV to Capital Employed
-27.34
EV to Sales
0.87
PEG Ratio
0.34
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
3.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 45.10% vs 1,175.00% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is -1,100.00% vs 73.33% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.40",
          "val2": "5.10",
          "chgp": "45.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.10",
          "val2": "-0.20",
          "chgp": "150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-0.40",
          "chgp": "-1,100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4.10%",
          "val2": "-55.50%",
          "chgp": "5.14%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.80",
          "val2": "2.30",
          "chgp": "673.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.20",
          "val2": "-3.90",
          "chgp": "94.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.50",
          "chgp": "-20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.20",
          "val2": "-4.60",
          "chgp": "73.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-48.20%",
          "val2": "-1,843.70%",
          "chgp": "179.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - YoYstock-summary
Apr'25
Apr'24
Change(%)
Net Sales
7.40
5.10
45.10%
Operating Profit (PBDIT) excl Other Income
0.10
-0.20
150.00%
Interest
0.00
0.10
-100.00%
Exceptional Items
-4.80
0.00
Consolidate Net Profit
-4.80
-0.40
-1,100.00%
Operating Profit Margin (Excl OI)
-4.10%
-55.50%
5.14%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Apr 2025 is 45.10% vs 1,175.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is -1,100.00% vs 73.33% in Apr 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jul'24stock-summary
Jul'24
Jul'23
Change(%)
Net Sales
17.80
2.30
673.91%
Operating Profit (PBDIT) excl Other Income
-0.20
-3.90
94.87%
Interest
0.40
0.50
-20.00%
Exceptional Items
0.00
-0.00
Consolidate Net Profit
-1.20
-4.60
73.91%
Operating Profit Margin (Excl OI)
-48.20%
-1,843.70%
179.55%
USD in Million.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About Devonian Health Group, Inc. stock-summary
stock-summary
Devonian Health Group, Inc.
Pharmaceuticals & Biotechnology
Devonian Health Group In is a late stage Canada-based botanical and pharmaceutical company. The Company adopts a therapeutic approach, which targets various worldwide unmet medical needs. The core business of the Company is the development of prescription botanical drugs, as well as derma-cosmeceutical products, which is divided into two main segments: Therapeutics and Derma-cosmeceuticals. The Therapeutics segment includes Thykamine, which is an active lead drug candidate confirmed in a number of pre-clinical and clinical studies targeting inflammation. The Derma-cosmeceuticals includes the first derma-cosmeceutical product of the Company, which is a women’s anti-aging treatment consisting of day, night and eye creams.
Company Coordinates stock-summary
Company Details
115 Frontenac Ave , POINTE-CLAIRE QC : H9R 4Z7
stock-summary
Tel: 1 450 9376696
stock-summary
http://groupedevonian.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."